Skip to main content
. 2022 Jan 4;52(3):273–292. doi: 10.1007/s40005-021-00558-4

Fig. 2.

Fig. 2

Schematic configurations of several types of microneedle (MN) systems and physical delivery systems combined with MN for nucleic acid drug delivery [immediately after application (upper) and after drug distribution (lower)]